Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 3/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | CCR4 | P51679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817183 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2C19CCR2NPBWR1MCHR1 | |
| SCHEMBL3148407 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2C19CCR2NPBWR1MCHR1 | |
| SCHEMBL3713847 | 0.95 | NPBWR1 (0.54) | CYP1A2CYP2C19CCR2NPBWR1MCHR1 | |
| SCHEMBL3713849 | 0.95 | NPBWR1 (0.54) | CYP1A2CYP2C19CCR2NPBWR1MCHR1 | |
| SCHEMBL5702015 | 0.90 | S1PR5 (0.46) | CCR2NPBWR1MCHR1GAACD274 | |
| SCHEMBL5701943 | 0.90 | S1PR5 (0.46) | CCR2NPBWR1MCHR1GAACD274 | |
| SCHEMBL2587055 | 0.87 | CYP1A2 (0.60) | CYP1A2CYP2C19MCHR1SPHK1SMN1; SMN2 | |
| SCHEMBL1819248 | 0.87 | CYP1A2 (0.60) | CYP1A2CYP2C19MCHR1SPHK1SMN1; SMN2 | |
| SCHEMBL1972076 | 0.87 | CYP1A2 (0.60) | CYP1A2CYP2C19MCHR1SPHK1SMN1; SMN2 | |
| SCHEMBL7781292 | 0.86 | CYP1A2 (0.50) | CYP1A2CYP2C19SPHK1SMN1; SMN2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-10174077-B2 | Method of inhibiting activity of cell surface fibroblast activation protein alpha | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2019-01-08 | — | — | US | disclosed |
| US-10155789-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2018-12-18 | — | — | US | disclosed |
| WO-2018178397-A1 | N-ALKYLATED AMINO ACIDS AND OLIGOPEPTIDES, USES THEREOF AND METHODS FOR PROVIDING THEM. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2018-10-04 | — | — | WO | disclosed |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3275440-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | National Center for Geriatrics and Gerontology (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-20170260231-A1 | Substrates and Inhibitors of Prolyl Oligopeptidase and Methods of Use Thereof | UNIV OKLAHOMA (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688722-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066800-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | UNIV OKLAHOMA (US) | 2017-03-09 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| CN-101512338-A | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use thereof | MCKEE PATRICK A (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2038653-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | McKee, Patrick A. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| CN-101123962-A | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS INC (US) | 2008-02-13 | — | — | CN | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CYP1A2 130/4885CYP2C19 186/4885CCR2 642/4885 |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | CYP1A2 328/4885CYP2C19 632/4885CCR2 1184/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CYP1A2 2416/4885CYP2C19 3287/4885CCR2 1432/4885 |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | APP, BACE1, PSEN1 | CYP1A2 1294/4885CYP2C19 715/4885CCR2 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.